There has been a major debate in Canada about whether we need
a national pharmacare program. This debate has involved a wide
range of policy actors, including: academics pharmaceutical
companies, private and public drug insurers, patient advocates,
employers, unions and political parties.
First,
what is the evidence supporting or opposing establishing such a
program? Second, if Canada decided to implement it, what challenge
would it face in doing so?